loratadine has been researched along with Rhinitis in 25 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Rhinitis: Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to compare the efficacy and safety of a once-daily loratadine-pseudoephedrine sustained release tablet with that of a twice-daily loratadine-pseudoephedrine in the treatment of patients with allergic rhinitis." | 9.12 | A randomized, double-blind, parallel-group study to compare the efficacy and safety of a once-daily loratadine-pseudoephedrine combination with that of a twice-daily loratadine-pseudoephedrine combination in the treatment of allergic rhinitis. ( Chang, KP; Chen, YA; Hao, SP; Lin, YS, 2007) |
| "The objective of the study is to assess the efficacy of the nonsedating antihistamine, desloratadine, in the treatment of allergic rhinitis (AR)." | 8.84 | Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. ( Canonica, GW; Compalati, E; Penagos, M; Tarantini, F, 2007) |
| "The loratadine treated group had better results both in nasal symptoms, with a decrease in sneezing (P < 0." | 6.69 | A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES). ( Bagnato, GF; Barresi, L; Gangemi, S; Isola, S; Purello-D'Ambrosio, F; Ricciardi, L, 1999) |
| " First, we constructed a dose-response curve." | 5.33 | Acute bacterial rhinosinusitis causes hyperresponsiveness to histamine challenge in mice. ( Kirtsreesakul, V; Klemens, JJ; Luxameechanporn, T; Naclerio, RM, 2005) |
| "The aim of this study is to compare the efficacy and safety of a once-daily loratadine-pseudoephedrine sustained release tablet with that of a twice-daily loratadine-pseudoephedrine in the treatment of patients with allergic rhinitis." | 5.12 | A randomized, double-blind, parallel-group study to compare the efficacy and safety of a once-daily loratadine-pseudoephedrine combination with that of a twice-daily loratadine-pseudoephedrine combination in the treatment of allergic rhinitis. ( Chang, KP; Chen, YA; Hao, SP; Lin, YS, 2007) |
| "In a double-blind, randomized study 62 patients with grass pollen-induced allergic rhinitis received a nasal glucocorticoid (fluticasone propionate aqueous nasal spray [FPANS], 200 microg/d), an antileukotriene (montelukast, 10 mg/d), a combination of montelukast with an antihistamine (loratadine, 10 mg/d), or placebo throughout the season." | 5.10 | Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. ( Lötvall, J; Praks, L; Pullerits, T; Ristioja, V, 2002) |
| "The objective of the study is to assess the efficacy of the nonsedating antihistamine, desloratadine, in the treatment of allergic rhinitis (AR)." | 4.84 | Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. ( Canonica, GW; Compalati, E; Penagos, M; Tarantini, F, 2007) |
| "Histamine and cysteinyl leukotrienes are pivotal mast cell mediators which contribute considerably and likely complementary to the symptoms of allergic rhinitis." | 3.76 | Concomitant activity of histamine and cysteinyl leukotrienes on porcine nasal mucosal vessels and nasal inflammation in the rat. ( Hunter, JC; Jia, Y; Jimenez, J; Lieber, G; McLeod, RL, 2010) |
| "Sneezing and nasal scratching after challenges were significantly ameliorated in the Shu-Bi-Lin-treated group compared with the ovalbumin-sensitized and untreated group, but rhinorrhea volume was not reduced." | 3.73 | Effect of a Chinese herbal formula, Shi-Bi-Lin, on an experimental model of allergic rhinitis. ( Chen, GG; Leung, PC; van Hasselt, CA; Wang, LH; Wong, YO; Woo, JK; Zhao, Y, 2006) |
| "The loratadine treated group had better results both in nasal symptoms, with a decrease in sneezing (P < 0." | 2.69 | A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES). ( Bagnato, GF; Barresi, L; Gangemi, S; Isola, S; Purello-D'Ambrosio, F; Ricciardi, L, 1999) |
| "Loratadine is an especially effective second-generation H1-receptor antagonist and is comparable to many of the other second-generation antihistamines." | 2.38 | Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine. ( Danzig, MR; Roman, IJ, 1993) |
| " First, we constructed a dose-response curve." | 1.33 | Acute bacterial rhinosinusitis causes hyperresponsiveness to histamine challenge in mice. ( Kirtsreesakul, V; Klemens, JJ; Luxameechanporn, T; Naclerio, RM, 2005) |
| "Allergic rhinitis is manifested by watery discharge; however its clinical effect on the watery volume in the oral cavity is unknown." | 1.33 | Saliva secretion in patients with allergic rhinitis. ( Elad, S; Heisler, S; Shalit, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 16 (64.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, J | 1 |
| Kan, D | 1 |
| Jie, Q | 1 |
| Kodithuwakku, ND | 1 |
| Yuan, X | 1 |
| He, G | 1 |
| Chen, M | 1 |
| Xu, S | 1 |
| Wu, Y | 1 |
| Lieber, G | 1 |
| Jimenez, J | 1 |
| Hunter, JC | 1 |
| McLeod, RL | 1 |
| Jia, Y | 1 |
| Farrokhi, S | 1 |
| Mousavi, T | 1 |
| Arshi, S | 1 |
| Javahertarash, N | 1 |
| Varasteh, A | 1 |
| Falak, R | 1 |
| Rezaei, N | 1 |
| Salekmoghadam, A | 1 |
| Wasserman, N | 1 |
| Andersson, M | 1 |
| Persson, CG | 1 |
| Svensson, C | 1 |
| Cervin-Hoberg, C | 1 |
| Greiff, L | 1 |
| Chester, AC | 1 |
| Passalacqua, G | 1 |
| Guerra, L | 1 |
| Compalati, E | 2 |
| Massacane, P | 1 |
| Rogkakou, A | 1 |
| Zanella, C | 1 |
| Baena-Cagnani, R | 1 |
| Canonica, GW | 2 |
| Georgalas, C | 1 |
| Thomas, K | 1 |
| Owens, C | 1 |
| Abramovich, S | 1 |
| Lack, G | 1 |
| Klemens, JJ | 1 |
| Kirtsreesakul, V | 1 |
| Luxameechanporn, T | 1 |
| Naclerio, RM | 1 |
| Zhao, Y | 1 |
| van Hasselt, CA | 1 |
| Woo, JK | 1 |
| Chen, GG | 1 |
| Wong, YO | 1 |
| Wang, LH | 1 |
| Leung, PC | 1 |
| Elad, S | 1 |
| Heisler, S | 1 |
| Shalit, M | 1 |
| Layton, D | 1 |
| Wilton, L | 1 |
| Boshier, A | 1 |
| Cornelius, V | 1 |
| Harris, S | 1 |
| Shakir, SA | 1 |
| Mullol, J | 1 |
| Valero, A | 1 |
| Alobid, I | 1 |
| Tarantini, F | 1 |
| Penagos, M | 1 |
| Chen, YA | 1 |
| Chang, KP | 1 |
| Lin, YS | 1 |
| Hao, SP | 1 |
| Kiratli, H | 1 |
| Onder, S | 1 |
| Yildiz, S | 1 |
| Ozşeker, H | 1 |
| Roman, IJ | 1 |
| Danzig, MR | 1 |
| Horak, F | 1 |
| Toth, J | 1 |
| Hirschwehr, R | 1 |
| Marks, B | 1 |
| Stübner, UP | 1 |
| Jäger, S | 1 |
| Berger, U | 1 |
| Schleinzer, K | 1 |
| Günczler, P | 1 |
| Wroblewski, BA | 1 |
| Purello-D'Ambrosio, F | 1 |
| Isola, S | 1 |
| Ricciardi, L | 1 |
| Gangemi, S | 1 |
| Barresi, L | 1 |
| Bagnato, GF | 1 |
| Hansen, GR | 1 |
| Wilson, AM | 1 |
| Pullerits, T | 1 |
| Praks, L | 1 |
| Ristioja, V | 1 |
| Lötvall, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
4 reviews available for loratadine and Rhinitis
| Article | Year |
|---|---|
Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials.
Topics: Double-Blind Method; Histamine H1 Antagonists, Non-Sedating; Humans; Hypersensitivity; Loratadine; N | 2007 |
Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine.
Topics: Animals; Drug Therapy, Combination; Ephedrine; Humans; Loratadine; Rhinitis; Urticaria | 1993 |
Loratadine in the high performance aerospace environment.
Topics: Adult; Aerospace Medicine; Anti-Allergic Agents; Histamine H1 Antagonists; Humans; Loratadine; Milit | 1999 |
Are antihistamines useful in managing asthma?
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchospirometry; Cetirizine; Cyclopropa | 2002 |
7 trials available for loratadine and Rhinitis
| Article | Year |
|---|---|
Effects of loratadine on red wine-induced symptoms and signs of rhinitis.
Topics: Adolescent; Adult; Aged; alpha-Macroglobulins; Case-Control Studies; Cross-Over Studies; Double-Blin | 2003 |
Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours.
Topics: Adolescent; Adult; Cetirizine; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; M | 2004 |
Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England.
Topics: Adult; Cetirizine; Cohort Studies; Conscious Sedation; Drug Monitoring; England; Female; Histamine H | 2006 |
A randomized, double-blind, parallel-group study to compare the efficacy and safety of a once-daily loratadine-pseudoephedrine combination with that of a twice-daily loratadine-pseudoephedrine combination in the treatment of allergic rhinitis.
Topics: Adult; Anti-Allergic Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combin | 2007 |
Effect of continuous allergen challenge on clinical symptoms and mediator release in dust-mite-allergic patients.
Topics: Adult; Antigens, Dermatophagoides; Blood Proteins; Bronchial Provocation Tests; Chymases; Cross-Over | 1998 |
A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES).
Topics: Adult; Anti-Inflammatory Agents; Double-Blind Method; Drug Therapy, Combination; Eosinophilia; Eosin | 1999 |
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis.
Topics: Acetates; Administration, Intranasal; Adult; Androstadienes; Circadian Rhythm; Cyclopropanes; Double | 2002 |
14 other studies available for loratadine and Rhinitis
| Article | Year |
|---|---|
Evaluation of efficiency and safety of combined loratadine and budesonide in patients with anaphylactic rhinitis: A protocol for systematic review and meta-analysis.
Topics: Anaphylaxis; Budesonide; Child; Humans; Loratadine; Meta-Analysis as Topic; Research Design; Rhiniti | 2022 |
Anti-allergic and anti-inflammatory properties of a potent histamine H1 receptor antagonist, desloratadine citrate disodium injection, and its anti-inflammatory mechanism on EA.hy926 endothelial cells.
Topics: Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Capillary Permeability; Cell Survival; Chlo | 2015 |
Best drugs for what ails you: the brands to buy--and those to skip.
Topics: Acetaminophen; Anesthetics, Local; Cetirizine; Chlorpheniramine; Common Cold; Cough; Dextromethorpha | 2009 |
Concomitant activity of histamine and cysteinyl leukotrienes on porcine nasal mucosal vessels and nasal inflammation in the rat.
Topics: Acetates; Animals; Cyclopropanes; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Drug T | 2010 |
Effect of treatment with intranasal corticosteroid and oral antihistamine on cytokine profiles of peripheral blood mononuclear cells of patients with allergic rhinitis sensitive to chenopodium album.
Topics: Adult; Allergens; Androstadienes; Anti-Allergic Agents; Case-Control Studies; Chenopodium album; Cyt | 2010 |
Loratadine is viable in patients with geriatric rhinitis.
Topics: Aged; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis | 2002 |
Re: Effects of loratadine... by Andersson et al.
Topics: Anti-Allergic Agents; Case-Control Studies; Food Hypersensitivity; Humans; Loratadine; Randomized Co | 2004 |
Medical treatment for rhinosinusitis associated with adenoidal hypertrophy in children: an evaluation of clinical response and changes on magnetic resonance imaging.
Topics: Adenoids; Administration, Intranasal; Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Chil | 2005 |
Acute bacterial rhinosinusitis causes hyperresponsiveness to histamine challenge in mice.
Topics: Acute Disease; Animals; Dose-Response Relationship, Drug; Histamine; Histamine H1 Antagonists, Non-S | 2005 |
Effect of a Chinese herbal formula, Shi-Bi-Lin, on an experimental model of allergic rhinitis.
Topics: Animals; Anti-Allergic Agents; Disease Models, Animal; Drugs, Chinese Herbal; Eosinophils; Guinea Pi | 2006 |
Saliva secretion in patients with allergic rhinitis.
Topics: Adolescent; Adult; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Middle Aged; Patient | 2006 |
The nose - from symptoms to evidence-based medicine.
Topics: Conjunctivitis; Evidence-Based Medicine; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; | 2007 |
Eosinophilic angiocentric fibrosis of the orbit.
Topics: Adult; Eosinophilic Granuloma; Female; Fibrosis; Histamine H1 Antagonists, Non-Sedating; Humans; Hyp | 2008 |
Antihistamines.
Topics: Astemizole; Histamine H1 Antagonists; Humans; Loratadine; Rhinitis; Terfenadine | 1998 |